I. Somasundaram, B.V. Nagarjuna Yadav, S. Sathesh Kumar
I. Somasundaram*, B.V. Nagarjuna Yadav, S. Sathesh Kumar
Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Vels University, Chennai-600117, India
Volume - 9,
Issue - 7,
Year - 2016
Aim and Objectives The present investigation was undertaken to develop nanosuspension of a hydrophilic drug pramipexole dihydrochloride and improve the entrapment efficiency of the drug.
Materials and Methods: Nanosuspension of pramipexole dihydrochloride was prepared with PLGA and Pluronic F68 by the process of modified nanoprecipitation technique. The particle size, zeta potential, SEM, TEM and invitro dug release where performed. The cell viability study were performed by using SH-SY5Y cells.
Result and Discussion: Nano-formulations are prepared with different concentrations of PLGA. The formulation variables such as polymer concentration (PLGA) were found to possess significant effect on the particle size and entrapment efficiency of drug in nanosuspension .The maximum entrapment efficiency, least particle size and optimal invitro drug release profile were exhibited with 1;3 ratio having 1% concentration of Pluronic F 68. The least particle size of 195 nm and maximum zeta potential value 34.8 mv were observed with PPNP 3 formulation. The SEM, TEM and invitro dug release of PPNP 3 were performed shows spherical shape with controlled release when compared to other formulations. Further the MTT assay were performed by using SH-SY5Y cells which shows more cell viability with PPNP 3 nanoformulation when compared to pure drug.
Conclusion: PPNP 3 can be selected as best formulation among the other formulations. Thus, the biodegradable poly mer influences a better delivery in brain for the treatment in Parkinson’s disease
Cite this article:
I. Somasundaram, B.V. Nagarjuna Yadav, S. Sathesh Kumar. Formulation of PLGA Polymeric Nanosuspension containing Pramipexole Dihydrochloride for improved treatment of Parkinson’s Diseases. Research J. Pharm. and Tech. 2016; 9(7):810-816 . doi: 10.5958/0974-360X.2016.00155.4